Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
NCT07601425
This study is recruiting at 6 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a 2-part study evaluating ATV-1601 in participants with moderate to severe HHT. Part 1 is a randomized, double-blind, placebo-controlled study evaluating 3 dosing regimens of ATV-1601. Patients completing Part 1 may participate in the Part 2 open-label extension to receive ATV-1601.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Hereditary Hemorrhagic Telangiectasia (HHT)
- Osler Weber Rendu Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Atavistik Bio, Inc
- Last updated on ClinicalTrials.gov
- October 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Arizona Pulmonary Specialists · Phoenix, AZ
Georgia · 1
- Augusta University Medical Center · Augusta, GA
Indiana · 1
- Innovative Hematology · Indianapolis, IN
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
Minnesota · 1
- Mayo Clinic · Rochester, MN
Utah · 1
- University of Utah Health Sciences Center · Salt Lake City, UT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.